Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||JNJ 38877605 + Panitumumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|JNJ 38877605||JNJ38877605|JNJ-38877605||MET Inhibitor 56||JNJ 38877605 binds to MET and prevents its activation, resulting in decreased downstream signaling and potentially resulting in increased cell death of MET-overexpressing tumor cells (PMID: 31881189, PMID: 30284817).|
|Panitumumab||Vectibix||ABX-EGF||EGFR Antibody 43||Vectibix (panitumumab) is a monoclonal antibody directed against EGFR, which inhibits cell proliferation and induces apoptosis (PMID: 18998757). Vectibix (panitumumab) is FDA approved for metastatic colorectal cancer patients with wild-type KRAS and NRAS (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|